<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945801</url>
  </required_header>
  <id_info>
    <org_study_id>GPPG-13-0272</org_study_id>
    <secondary_id>13-0272</secondary_id>
    <nct_id>NCT01945801</nct_id>
  </id_info>
  <brief_title>Sodium-Restricted Diet and Diuretic in the Treatment of Severe Sleep Apnea</brief_title>
  <acronym>DESALT</acronym>
  <official_title>The Effect of Sodium-Restricted Diet and Diuretic in the Severe Sleep Apnea: a Randomized Controlled Trial - DESALT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the intervention of the 1) sodium-restricted diet, or 2) diuretic, or 3)
      placebo pill in the treatment of obstructive sleep apnea in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Men with apnea-hypopnea index greater than 30/hour will be included and randomly assigned
      into three groups: sodium-restricted diet, or diuretic, or control. The intervention will
      last one week. The diuretic group will receive combined spironolactone 100mg plus furosemide
      20mg daily. The diet group will receive a regimen with a maximum intake of three grams of
      sodium per day. The control group will receive a placebo pill and will maintain all eating
      habits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea-Hypopnea Index</measure>
    <time_frame>One week</time_frame>
    <description>Number of apneas/hour</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Somnolence scale (Epworth) and ventilatory parameters</measure>
    <time_frame>One week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycolipid profile</measure>
    <time_frame>One week</time_frame>
    <description>Total and HDL Cholesterol, Triglycerides, and glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone Renin Level Activity</measure>
    <time_frame>One week</time_frame>
    <description>Serum renin and aldosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosages of urinary 24h</measure>
    <time_frame>One week</time_frame>
    <description>Aldosterone, sodium, potassium, urea, and creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker</measure>
    <time_frame>One week</time_frame>
    <description>C reactive protein</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Lasilactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosage form: One capsule taking in the morning Dosage: furosemide, 20mg, and spironolactone, 100 mg. Frequency and duration: One capsule daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium-Restricted Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The diet group will receive a regimen with a prescribed intake of three grams of sodium per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasilactone</intervention_name>
    <description>Active drug (spironolactone 100 mg plus furosemide 20 mg).</description>
    <arm_group_label>Lasilactone</arm_group_label>
    <other_name>Spironolactone 100 mg plus Furosemide 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium-Restricted Diet</intervention_name>
    <description>The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.</description>
    <arm_group_label>Sodium-Restricted Diet</arm_group_label>
    <other_name>Low sodium diet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.</description>
    <arm_group_label>placebo pill</arm_group_label>
    <other_name>Placebo pill</other_name>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men in the age range from 18 to 60 years

          -  Full-night in-laboratory polysomnography with apnea-hypopnea index &gt; 30/h in the last
             three months

          -  Body mass index &lt; 35 kg/m2

          -  Informed consent

        Exclusion Criteria:

          -  Already having started any treatment for sleep apnea, including use of continuous
             positive airway pressure

          -  NYHA heart failure, any class

          -  Predominantly central apnea

          -  Peripheral venous or lymphatic insufficiency

          -  Any chronic renal disease

          -  Use of diuretics and substances with action in the central or peripheral nervous
             system such as benzodiazepines, hypnotics, anticonvulsants, antidepressants, appetite
             suppressants, amphetamines, antiparkinson agents, muscle relaxants, bronchodilators

          -  Stroke within 6 months or with incapacitating sequelae

          -  Any physical, mental or social condition impairing the ability to participate in the
             trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Martinez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep apnea</keyword>
  <keyword>Treatment</keyword>
  <keyword>Sodium-Restricted Diet</keyword>
  <keyword>Diuretic</keyword>
  <keyword>Lasilactone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

